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Vγ9Vδ2-T cells are considered as potent effector cells for tumor immunotherapy through 
directly killing tumor cells and indirectly regulating other innate and adaptive immune 
cells to establish antitumoral immunity. The antitumoral activity of Vγ9Vδ2-T  cells is 
governed by a complicated set of activating and inhibitory cell receptors. In addition, 
cytokine milieu in tumor microenvironment can also induce the pro-tumoral activities 
and functional plasticity of Vγ9Vδ2-T cells. Here, we review the anti- versus pro-tumoral 
activities of Vγ9Vδ2-T  cells and discuss the mechanisms underlying the recognition, 
activation, differentiation and regulation of Vγ9Vδ2-T cells in tumor immunosurveillance. 
The comprehensive understanding of the dual face of Vγ9Vδ2-T cells in tumor immuno-
logy may improve the therapeutic efficacy and clinical outcomes of Vγ9Vδ2-T cell-based 
tumor immunotherapy.
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iNTRODUCTiON
Human γδ-T cells can be classified into two main subsets depending on the expression of T cell 
receptor (TCR) δ chain (1). Vδ1 γδ-T cells with different Vγ elements account for the majority of 
mucosal-associated lymphoid tissue γδ-T cells, and they mediate the immune responses to Listeria 
monocytogenes, Cytomegalovirus, and certain hematological malignancies (2, 3). In contrast, 
γδ-T  cells bearing the Vδ2 gene with the co-expression of the Vγ9 chain (Vγ9Vδ2-T  cells) are 
abundant in the peripheral blood and lymphoid organs of most healthy individuals, and they are 
involved in the first line of the immune responses to mycobacteria, Epstein–Barr virus (EBV), and 
some solid tumors (1, 2, 4–10).
The Vγ9Vδ2-T  cell is an important component of immune effector cells that contribute to 
tumor immunosurveillance against many types of tumors, such as lymphoma, myeloma (11, 12), 
hepatocellular, and colorectal carcinoma (13), and prostate (14), lung (15), colon (16), breast (17), 
and ovary cancers (18). Recently, our group discovered a novel strategy to treat EBV-induced B-cell 
lymphoma by boosting Vγ9Vδ2-T cell immunity (19, 20). Vγ9Vδ2-T cells can directly kill tumor 
cells through the secretion of cytolytic molecules or indirectly prime and modulate immunological 
functions of other innate and adaptive immune cells to develop and establish profound antitumor 
immunity (21, 22). Unlike the conventional αβ-T  cells, the Vγ9Vδ2-T  cell is a member of the 
non-conventional lymphocyte family (23), and the antigen recognition of Vγ9Vδ2-T cells is major 
histocompatibility complex (MHC)-unrestricted (24, 25). Recent growing evidence has suggested 
that the Vγ9Vδ2-T cell is one of the most attractive candidates for antitumor immunotherapy. In 
this review, we will discuss recent advances in the basic Vγ9Vδ2-T cell research and evidence from 
clinical applications of Vγ9Vδ2-T cells. Most importantly, this review will provide an overview of 
the current knowledge about mechanisms of Vγ9Vδ2-T cell mediated antitumor immunity and the 
potential limitations of Vγ9Vδ2-T cell-based immunotherapy.
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PLASTiCiTY OF vγ9vδ2-T CeLLS  
iN TUMOR iMMUNiTY
The antitumor activity of Vγ9Vδ2-T cells is influenced by their 
functional plasticity that is driven by environmental factors (26). 
Similar to αβ-T cells, Vγ9Vδ2-T cells also display the plasticity that 
contributes to their functional specialization (27). Accumulating 
evidence indicates that Vγ9Vδ2-T cells can differentiate into the 
cells with various characteristics associated with Th1-like, Th2-
like, Th17-like, follicular T helper cells (Tfh)-like, or regulatory 
T cells (Treg)-like characteristics (26).
Upon phosphoantigen stimulation, Vγ9Vδ2-T  cells pref-
erentially differentiate into Th1-like cells with profound IFN-γ 
and TNF-α responses (28, 29). Th1-like Vγ9Vδ2-T  cells can 
be induced through isopentenyl pyrophosphate (IPP) activa-
tion with IL-12 and anti-IL-4 antibody, and even the addition 
of IL-21 (30–32). Phosphoantigens and IL-2 can promote their 
cytolytic activity by upregulating CD56 expression and increas-
ing granule secretion (32, 33). Interestingly, Vγ9Vδ2-T cells can 
also be polarized into Th2-like cells, which are characterized by 
increased secretion of IL-4 upon stimulation with IPP, IL-4, and 
anti-IL-12 antibody (30).
Vγ9Vδ2-T  cells with Tfh-like functions can be induced by 
IL-21 and phosphoantigens stimulation (34, 35). These Tfh-like 
Vγ9Vδ2-T  cells also have the capability to migrate into the 
lymph node germinal center (35). Similar to Tfh CD4+ T-cells, 
cell-to-cell contact is necessary for the B cell helper activity of the 
Tfh-like Vγ9Vδ2-T cells.
IL-17-producing γδ-T cells have been extensively discussed 
in the murine model (36). Recent findings also suggested that 
human γδ-T  cells can produce IL-17 (37, 38). Some groups 
reported that naïve Vγ9Vδ2-T  cells can be induced into the 
Th17-like phenotype or mixed Th1/Th17-like phenotype 
(39–41). Vγ9Vδ2-T cells require IL-1β, IL-23, and TGF-β, but 
not IL-6, for differentiation into Th17-like cells (41). In human 
colorectal cancer (CRC), activated inflammatory dendritic cells 
(DCs) polarize Vγ9Vδ2-T cells into IL-17-producing γδ-T cells, 
which can secrete high levels of IL-17 in an IL-23-dependent 
manner (42).
Upon stimulation of IPP in the presence of IL-15 and TGF-
β, the Vγ9Vδ2-T cells can be induced into transcription factor 
forkhead box P3 (Foxp3)-expressing Treg-like γδ-T  cells with 
regulatory/immunosuppressive function (43). When combined 
with IL-15, IL-2, TGF-β, and phosphoantigen stimulation, 
decitabine can also induce the immunoregulatory activity of 
Vγ9Vδ2-T cells (44).
Therefore, Vγ9Vδ2-T  cells can be induced into different 
functional subsets depending on the cytokine milieu in the tumor 
microenvironment.
ANTiTUMORAL ReSPONSe OF  
vγ9vδ2-T CeLLS
The antitumoral activity of Vγ9Vδ2-T cells has been well studied 
(45, 46). Their antitumoral activity mostly relies on the recogni-
tion of phosphoantigens and stressed molecules by TCR (47) and 
other cellular receptors (48), like NKG2D (49). These receptors 
can respond to perturbations in the endogenous isoprenoid bio-
synthesis and the presence of “danger signals” that occur during 
cell stress and malignant transformation. Other molecules can 
act as co-stimulatory signals to regulate the antitumoral activ-
ity of Vγ9Vδ2-T  cells (48). Apart from the direct cytotoxicity 
of Vγ9Vδ2-T  cells, these cells can also stimulate and regulate 
other immune components to establish the antitumoral activity 
(7, 50). Last, but not least, the homing receptors expressed on 
Vγ9Vδ2-T  cells lead cell migration to tumor sites where they 
display broad and potent antitumoral activity (51).
Mechanisms of Tumor Cell Recognition
TCRγδ Recognition
Non-Peptide Ligands
In tumor immunosurveillance, although Vγ9Vδ2-T  cells share 
some features with other immune cells, such as NK  cells and 
αβ-T cells (21, 52), a distinctive characteristic of Vγ9Vδ2-T cells is 
the TCR-dependent recognition of non-peptidic phosphorylated 
antigens (also called phosphoantigens). Vγ9Vδ2-TCR recognizes 
the molecules that are normally expressed in specific conditions, 
such as when cells undergo stressful conditions. For example, 
(E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) 
and IPP are the products of the prokaryotic isoprenoid pathway 
and the mevalonate isoprenoid pathway, respectively (53–56). 
All of these products can be recognized by Vγ9Vδ2-T cells and 
lead to subsequent activation of Vγ9Vδ2-T  cells. The levels of 
these naturally occurring metabolites are too low to be detected 
as a dangerous signal by Vγ9Vδ2-T  cells in normal cells. The 
dysfunctional metabolism of malignant tumor cells can result in 
the accumulation of endogenous phosphoantigens that are recog-
nized by Vγ9Vδ2-T cells. Furthermore, bisphosphonates (such as 
pamidronate and zoledronate) can cause tumor cells to be more 
sensitive to the cytotoxicity of Vγ9Vδ2-T cells via inhibition of 
the farnesyl pyrophosphate synthase enzyme in the isoprenoid 
pathway, which leads to IPP accumulation (57). Meanwhile, 
current findings have indicated that several molecules, such 
as F1-ATPase (combined with apolipoprotein A-I, called Apo 
A-I) (58, 59) and butyrophilin 3A1 (BTN3A1, CD277), might 
be involved with phosphoantigens to mediate Vγ9Vδ2-T  cells 
activation (60, 61) (Figure 1).
Peptide Ligands
(1) Self ligands: in addition to non-peptide ligands, Vγ9Vδ2- 
T  cells can also recognize some molecules of cellular 
origin, which could be capable of indicating cellular stress 
or malignant transformation (49, 62). Several self-antigens 
have been confirmed to bind to Vγ9Vδ2-TCR, including 
heat shock protein-60 (HSP 60) (63), U16-binding protein 4 
(ULBP-4) (64), human MutS homolog 2 (hMSH2) (63, 65), 
and F1-ATP synthase (F1-ATPase) (59, 66). The expressions 
of these proteins are shown to be upregulated on the surface 
of different tumor cells and they can promote recogni-
tion by Vγ9Vδ2-T  cells. It is intriguing that ULBP-4 and 
hMSH2 can also bind to NKG2D to induce the cytotoxicity 
FigURe 1 | Underlying mechanisms implicated in regulating antitumoral activity of Vγ9Vδ2-T cells. Vγ9Vδ2-T cells can distinguish between tumorous and normal 
cells using T cell receptor (TCR) and other innate receptors to sense isopentenyl pyrophosphate (IPP) levels and stress signals (such as MICA/B, ULBP4, and MSH2) 
displayed on target cells. Most importantly, TCRγδ is the predominant factor that can trigger cell activation without any contribution of other co-stimulators, such as 
NKG2D. Following TCR-dependent activation, Vγ9Vδ2-T cells recognize and kill tumor cells by releasing effector molecules, such as granzymes and perforin, and 
Th-1 cytokines, inducing target cell apoptosis via Fas/FasL, TNF-related apoptosis-inducing ligand (TRAIL) and TNF-α pathways, and antibody-dependent 
cell-mediated cytotoxicity through CD16 expression. The activation threshold is finely regulated by inhibitory receptors, such as NKG2A/CD94. Moreover, adhesion 
patterns, such as lymphocyte function-associated antigen 1 (LFA-1)/intercellular adhesion molecule-1 (ICAM-1), are also involved in regulating the antitumoral activity 
of Vγ9Vδ2-T cells. The chemokine receptors, including CCR5, control the ability of Vγ9Vδ2-T cell to migrate to the tumor site. The survival and proliferation of 
Vγ9Vδ2-T cells are mostly modulated by different cytokines, such as IL-2 and IL-15.
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of Vγ9Vδ2-T  cells against tumor cells through TCR and 
NKG2D engagement (63–65) (Figure 1).
(2) Non-self ligands: tetanus toxoid (67), Ig λ light chain (68), 
and viral proteins, such as glycoprotein I from Herpes simplex 
(69) and staphylococcal enterotoxin A (70), are antigens that 
were reported to be capable of stimulating Vγ9Vδ2-T  cell 
responses.
Cell Receptor Engagement
Besides the Vγ9Vδ2-TCR engagement, some other cellular 
receptors, especially the NK receptors (NKRs), are involved 
in the effective triggering of antitumoral responses of 
Vγ9Vδ2-T cells (49) (Figure 1). Together with previous studies, 
we reported that NKG2D can bind to its ligands (71), such as 
MICA, MICB, and ULBP-1, -2, -3, and -4, which are expressed 
in different tumors, including leukemia, lymphoma, ovarian, 
and colon carcinoma (72–74). In particular, the high expres-
sion level of ULBP1 indicates the susceptibility of lymphoma to 
Vγ9Vδ2-T cell-mediated cytolysis (74). Furthermore, ULBP-4 
expression is detected on the cell surface of EBV-transformed 
lymphoid cells lines as well as on colon, ovarian, and liver cancer 
cells (64).
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Another NKR implicated in tumor recognition by Vγ9Vδ2- 
T cells is the DNAX accessory molecule-1 (DNAM-1) (75, 76). 
Nectin-like-5 and Nectin-2, ligands of DNAM-1, are expressed 
on most hepatocellular carcinoma (HCC) cell lines (75). In 
addition, some Vγ9Vδ2-T cells also express NKp44, which can 
mediate their cytotoxic activity against multiple myeloma (MM) 
cell lines (77, 78).
Similar to NK cells, Vγ9Vδ2-T cells also express high levels 
of CD16 (FcγR III) upon phosphoantigen stimulation (79), and 
thus leading to antibody-dependent cell-mediated cytotoxicity 
(ADCC) against tumor cells (80–83).
γδ-T CeLLS ACT AS eFFeCTOR CeLLS
vγ9vδ2-T Cells with Killer Functions
Interaction of TCR and/or NKG2D with their respective ligands 
can stimulate the activation of Vγ9Vδ2-T cells. Once activated, 
Vγ9Vδ2-T cells secrete IFN-γ and TNF-α, and increase the release 
of antitumor effector molecules, such as perforin and granzymes. 
The DNAM-1 signaling pathway can positively regulate the 
cytotoxic activity and IFN-γ secretion of Vγ9Vδ2-T cells against 
a broad range of tumors.
Antibody-dependent cell-mediated cytotoxicity mediated by 
Vγ9Vδ2-T  cells can be activated via the binding of CD16 to 
antibodies, such as rituximab, trastuzumab, atumumab, and 
alemtuzumab, coated on the certain tumor cells (80–83).
In addition, activated Vγ9Vδ2-T cells can also induce tumor 
cell apoptosis via TNF-related apoptosis-inducing ligand and 
Fas/FasL pathways (84–86).
vγ9vδ2-T Cells with Helper Functions
Activated Vγ9Vδ2-T  cells may secrete chemokines, such as 
C-C motif chemokine ligand 3 (CCL3), CCL4, C-X-C motif 
chemokine 10 (CXCL10), and CXCL13, to recruit αβ-T  cells, 
B cells, NK cells, and macrophages/DCs to the tumor site (22, 31, 
87). Activated Vγ9Vδ2-T cells not only stimulate DC maturation 
and macrophage activation (88, 89), but also induce CD4+ and 
CD8+ αβ-T cell differentiation for enhancing antitumoral activity 
through secretion of IFN-γ and TNF-α and upregulation of CD40L 
expression (88, 90, 91). Moreover, activated Vγ9Vδ2-T cells can 
mimic antigen presentation cell (APC) functions by stimulating 
the antitumoral activity of αβ-T cells through the upregulation of 
several surface molecules, such as MHC I and II, CD40, CD83, 
and CD86 (92, 93). Activated Vγ9Vδ2-T  cells can also present 
glycolipid antigens to iNKT cells through the uptake of CD-1d 
by trogocytosis. Subsequently, activated iNKT  cells can trigger 
downstream reactions to boost antitumoral immunity (94). 
Furthermore, activated CD137L+ Vγ9Vδ2-T cells can stimulate 
the antitumoral activity of NK cells by acting as a co-stimulator 
through interacting with CD137 expressed on NK  cells. Thus, 
the costimulatory signals can upregulate the cytotoxic activity of 
NK cells to kill the solid tumor cells, which usually show resist-
ance to NK cells (95). Although the contribution of IL-17 in tumor 
surveillance is still controversial (96–99), some in vitro and in vivo 
evidence have indicated that IL-17 secreted by Vγ9Vδ2-T  cells 
might be involved in antitumoral immune responses via indirect 
mechanisms (96) (Figure 2).
vγ9vδ2-T Cells with Homing Functions
CC and CXC chemokines are produced by most tumor cells, 
such as breast, cervix, pancreatic, and ovarian tumor cells 
(57). To provide optimal protection against tumor cells, the 
cytotoxic Vγ9Vδ2-T  cells must migrate from the blood-
stream to tumor site (33, 100, 101) (Figure  2). Unlike Vδ1 
γδ-T  cells which express lymph node homing chemokine 
receptor C-C chemokine receptor 7 (CCR7), the circulating 
Vγ9Vδ2-T  cells preferentially express inflammatory homing 
chemokine receptor CCR5, which can mediate the migration 
of Vγ9Vδ2-T  cells to CCR5 ligands that are expressed in 
tumor cells (20, 102). Apart from the predominantly expressed 
CCR5, Vγ9Vδ2-T cells also express other chemokine receptors 
including CCR1, CCR8, and C-X-C motif chemokine recep-
tor 3, which are involved in regulating the homing ability of 
Vγ9Vδ2-T cells (13, 87, 103).
In addition, some of the adhesion molecules, such as lym-
phocyte function-associated antigen 1 (LFA-1), L-selectin, and 
CD44v6, are also involved in the migration of Vγ9Vδ2-T cells to 
the tumor site (104) (Figure 1).
RegULATiON MeCHANiSMS OF γδ-T 
CeLL ACTivATiON
vγ9vδ2-T Cell Activation
In tumor immunosurveillance, the antitumoral activities of 
Vγ9Vδ2-T cells is composed of several steps (23): (1) detecting 
and sensing any types of stress signals in a non-MHC-restricted 
manner; (2) producing a huge quantity of effector molecules that 
can kill tumor cells through direct and indirect mechanisms; 
and (3) exhibiting potent cytotoxic and cytolytic activities 
against a broad panel of tumors. In order to tightly monitor the 
initiation and development of tumorigenesis, the activation of 
Vγ9Vδ2-T cells is triggered by TCR-mediated recognition and 
precisely regulated by various innate immune cells and cytokine 
receptors. Furthermore, the activation and differentiation of 
Vγ9Vδ2-T cells are molecularly controlled by surface receptors 
that capture key extracellular cues and convey downstream intra-
cellular signals (105). More detailed information can be found in 
Figure 1.
Regulation of vγ9vδ2-T Cell Activation
Regulation by TCR
Vγ9Vδ2-T  cells mainly recognize the non-peptide ligands, 
phosphoantigens, which are shown to act as a trigger signal to 
activate Vγ9Vδ2-T cells (105). Cipriani et al. concluded that IPP 
induces rapid and persistent PKC-dependent phosphorylation of 
ERK 1/2, p38 MAPK, and JNK, which can lead to the activation 
of NF-κB and AP-1 and the secretion of IFN-γ and TNF-α (106). 
Some studies have shown that crosslinking of CD3 and phos-
phoantigens stimulation can induce highly sustained calcium 
signaling in Vγ9Vδ2-T cells via phosphorylation of Zap70, Pi3K, 
LAT, ERK 1/2, and p38 MAPK (105, 107, 108).
Due to upregulated self-antigen expressions in the transformed 
tumor cells, Vγ9Vδ2-T cells discriminate these malignant cells 
by directly binding to these self-antigens (49), such as HSP 60, 
FigURe 2 | Schematic overview of immunological roles of Vγ9Vδ2-T cells in antitumoral surveillance. Vγ9Vδ2-T cells can make multiple contributions to antitumoral 
immunity, including “eFFeCToR” function and “HeLPeR” function. There are five steps involved in Vγ9Vδ2-T cell-associated effector functions: (1) Activation: upon 
stimulation by N-BPs (such as the administration of pamidronate) and increased-endogenous IPP produced by tumor cells, peripheral blood Vγ9Vδ2-T cells are 
activated in a T cell receptor-dependent manner. (2) Migration: the activated Vγ9Vδ2-T cells with an upregulated expression of chemokine receptors are recruited by 
gradient chemokines established by tumor cells. (3) Cytotoxicity: the infiltrating Vγ9Vδ2-T cells can recognize and kill tumor cells in the tumor site. (4) 
Immunosuppression: in the tumor microenvironment, tumor cells and other cells (like stromal cells and TAMs) produce immunosuppressive cytokines to induce the 
polarization of Vγ9Vδ2-T cells with Th-17 and Treg characteristics. Furthermore, the antitumoral activity of Vγ9Vδ2-T cells can be inhibited through the interaction of 
the inhibitory receptor and their corresponding ligands that are expressed by tumor cells and TAMs. (5) Pro-tumor: the polarized Vγ9Vδ2-T cells can secret IL-17 to 
support tumor growth directly. Moreover, IL-4, IL-10, IL-17, and TGF-β produced by the polarized Vγ9Vδ2-T cells not only recruit immunosuppressive MDSCs but 
also suppress innate and adaptive immune responses. Besides the “eFFeCToR” function, Vγ9Vδ2-T cells can also exhibit the “HeLPeR” functions in antitumor 
immune immunity. The activated Vγ9Vδ2-T cells can promote the maturation of DCs and the activation of macrophages. These Vγ9Vδ2-T cells can act as APC and 
initiate the differentiation and stimulation of tumor antigen-specific CD4+ T and CD8+ T cells. Moreover, Vγ9Vδ2-T cells can present antigens to iNKT and B cells. 
Vγ9Vδ2-T cells can promote NK cell antitumor response by delivering a costimulatory signal. APC, antigen presentation cell; DCs, dendritic cells; iNKT, invariant 
NKT cells; IPP, isopentenyl pyrophosphate; MDSCs, myeloid-derived suppressor cells; NK, natural killer cell; N-BPs, nitrogen-containing bisphosphonates; and 
TAMs, tumor-associated macrophages.
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ULBP-4, hMSH2, and F1-ATPase, which can enhance the activa-
tion and cytotoxicity of Vγ9Vδ2-T cells.
Regulation by NK-Associated Receptors
The expression of NK-associated receptors is a distinguishing 
feature of Vγ9Vδ2-T cells that mediates the recognition of stress 
ligands expressed by normal cells during infection and cell trans-
formation by different pathogens. NKG2D and its ligands, such as 
MICA/B and ULBPs (64, 74, 109), are well-defined NK-associated 
receptors and ligands for Vγ9Vδ2-T cells. For example, expres-
sions of these ligands are normally induced during cellular stress, 
such as DNA damage that occurs in tumor cells.
Whether NKG2D plays a primary stimulatory or a co-stim-
ulatory role in Vγ9Vδ2-T cells is still being debated (49). Some 
evidence have indicated that an additive effect of the NKG2D 
pathway on TCR-mediated activation through increasing 
cytokine production (110), and upregulating intracellular cal-
cium mobilization and enhancing cytotoxic activity (105). On 
the other hand, other studies have reported that the NKG2D 
pathway alone can activate Vγ9Vδ2-T  cells without TCR 
engagement (111), and the blockade of the NKG2D pathway, 
but not the blockade of γδ-TCR, can inhibit the cytotoxicity of 
Vγ9Vδ2-T cells against some hematological tumors (74).
DNAX accessory molecule-1 is another NK-associated recep-
tor that regulates Vγ9Vδ2-T cells, whereby blocking the interac-
tion between DNAM-1 and its ligands, such as Nectin-like-5 
and Nectin-2, could impair the cytotoxic capacity and IFN-γ 
production of Vγ9Vδ2-T cells against HCC cells (75).
A recent study demonstrated that NKp44, a natural cytotox-
icity receptor, is involved in the cytotoxicity of Vγ9Vδ2-T cells 
against MM cell lines that lack the expression of NKG2D ligands 
(77). Because Vγ9Vδ2-T cells are potentially highly self-reactive, 
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TCR-mediated activity needs to be tightly controlled by a close 
interplay between activating and inhibitory NKRs (105). Like 
NK  cells, most human circulating Vγ9Vδ2-T  cells express 
several inhibitory NKRs belonging to the lectin-like receptor 
family (such as the NKG2A/CD94 heterodimer), or the immu-
noglobulin (Ig) family [such as Ig-like transcript 2 (ILT-2)]. 
Upon interaction with the classical and/or non-classical MHC 
I molecules, the inhibitory signals are delivered by these recep-
tors to Vγ9Vδ2-T cells. This mechanism allows TCR-activated 
Vγ9Vδ2-T  cells to target the tumor cells rather than the 
normal cells depending on the expression level of the MHC I 
molecules, and thus preventing self-reactivity while enhancing 
antitumoral activity (105). In addition, NKG2C/CD94 also can 
regulate Vγ9Vδ2-T cell effector functions, including cytokine 
secretion, cell proliferation, and cytotoxic activity (112).
Regulation by Co-Stimulatory Receptors
There are two main types of costimulatory receptors that are 
expressed on Vγ9Vδ2-T cells: the Ig and tumor necrosis fac-
tor receptor (TNFR) superfamilies. Ribot et al. suggested that 
CD28, which is an important member of the Ig superfamily, 
is constitutively expressed on lymphoid Vγ9Vδ2-T  cells. 
Co-stimulation with CD28 promotes the survival and pro-
liferation of Vγ9Vδ2-T  cells by enhancing IL-2 production, 
whereas blocking antibodies target its B7 ligands (CD80 and 
CD86) can inhibit cell survival and proliferation (113). CD27 
is a member of the TNFR superfamily that is expressed in 80% 
of Vγ9Vδ2-T cells (114). CD27 pathway has been confirmed to 
play critical roles in co-stimulating Vγ9Vδ2-T cell activation. 
Furthermore, CD27 is also involved in promoting cell prolifera-
tion, upregulating the antiapoptotic gene Bcl2a1 to maintain 
cell survival and enhancing IFN-γ production and cytotoxic-
ity of Vγ9Vδ2-T  cells (105, 114). Upon activation, CD30, 
another member of the TNFR superfamily, is also expressed 
on Vγ9Vδ2-T  cells and it can increase pro-inflammatory 
cytokine production and promote TCR-induced calcium fluxes 
(115). A high level of CD137L that is expressed on activated 
Vγ9Vδ2-T  cells can transmit a reversal signal to regulate 
Vγ9Vδ2-T cell activation (95, 116).
Regulation by Adhesion Molecules
In addition to TCR and NKR, other surface receptors, such as 
adhesion molecules, are also important for regulating Vγ9Vδ2- 
T cell function. To date, several adhesion molecules, including 
LFA-1/intercellular adhesion molecule-1 (ICAM-1) (117), CD2/
LFA-1/3 (118), and CD6/CD166 (119), have been identi fied as 
regulators in modulating Vγ9Vδ2-T cell activation.
High expressions of LFA-1 and its ligand, ICAM-1, have been 
detected on the surface of Vγ9Vδ2-T cells and most of the tumor 
cell lines, respectively. LFA-1/ICAM-1 adhesive interaction is 
necessary but not sufficient for IFN-γ production and the cyto-
toxicity of Vγ9Vδ2-T cells (117). The interaction between LFA-3 
on Vγ9Vδ2-T  cells and CD2 on lymphoid cells can stimulate 
TNF-α secretion by Vγ9Vδ2-T cells (118). Additionally, CD6 is a 
member of the scavenger receptor family, which is also expressed 
on the surface of Vγ9Vδ2-T cells. CD6 binds to its ligand, CD166, 
which is associated with the capability of tumor cells to activate 
Vγ9Vδ2-T cells upon phosphoantigen induction (119).
Most importantly, the interactions between LFA-1/ICAM-1 
and CD2/LFA-3 can stabilize the immunological synapses after 
Vγ9Vδ2-TCR/phosphoantigen triggers the formation of immu-
nological synapses (120, 121).
Regulation by Toll-Like Receptors (TLRs)
The roles of TLRs in regulating the activation of Vγ9Vδ2-T cells 
are not completely understood. After ligation of TLR2, TLR3, 
and TLR5, the Vγ9Vδ2-T  cells can produce IFN-γ, TNF-α, 
granulocyte-macrophage colony-stimulating factor, CCL3, and 
CCL5 (122). The triggering of TLR3, 4, 5, and 9 can also induce 
the early activation of Vγ9Vδ2-T cell and the production of IFN-
γ (105). In addition, TLR3 and TLR7 agonists can enhance the 
antitumoral activity of Vγ9Vδ2-T cells against adenocarcinoma 
cells (123). Nevertheless, these responses require simultaneous 
stimulation of Vγ9Vδ2-TCR (105).
Regulation by Cytokine Receptors
The interleukin receptors are essential for the development and 
homeostasis of Vγ9Vδ2-T cells due to the pivotal effect of inter-
leukins on cell proliferation, differentiation, and survival, and the 
regulation of the immunological functions of the Vγ9Vδ2-T cells. 
IL-2 and IL-15 can be used to stimulate Vγ9Vδ2-T cell expansion, 
but they cannot fully induce effector functions without γδ-TCR-
mediated activation and downstream signals, such as the ERK 
and AKT pathway (124, 125). IL-12 and IL-18 are reported to be 
beneficial for differentiation into IFN-γ+ Vγ9Vδ2-T cells (126). 
Recent studies also indicated that other interleukins, such as 
IL-23, IL-1β (39, 40, 127), and IL-21 (34, 35), are also involved in 
the induction of Vγ9Vδ2-T cell plasticity.
Regulation by Inhibitory Receptors
Like inhibitory NKRs, some other inhibitory molecules, such as 
programmed cell death protein-1 (PD-1) and B- and T-lymphocyte 
attenuator (BTLA), act in a similar manner in Vγ9Vδ2-T cells. 
PD-1 and BTLA can negatively regulate Vγ9Vδ2-T  cell 
res ponses. Vγ9Vδ2-T  cells do not normally express detect-
able PD-1; however, once activated, the expression of PD-1 is 
upregulated in Vγ9Vδ2-T  cells (128). Iwasaki et  al. found that 
the interaction of PD-1 and PD-L1 can attenuate the antitumoral 
activity of Vγ9Vδ2-T  cells by downregulating IFN-γ produc-
tion and lowering cytotoxicity (128). BTLA engagement can 
downregulate phosphoantigen/γδ-TCR-mediated signaling and 
inhibit Vγ9Vδ2-T  cell proliferation, including the response to 
lymphoma cells (129). Moreover, the HLA-G expressed on the 
surface of tumor cells can bind to the ILT-2 on Vγ9Vδ2-T cells. 
This interaction could impair cytokine production and the cyto-
toxicity of Vγ9Vδ2-T cells (130).
PRO-TUMORAL ReSPONSe  
OF vγ9vδ2-T CeLLS
Recently, more evidence indicates that Vγ9Vδ2-T  cells can 
display the functions for promoting tumor development 
FigURe 3 | Antitumoral versus pro-tumoral activities of human 
Vγ9Vδ2-T cells. Vγ9Vδ2-T cells display dual effects in the immune 
surveillance against tumors, including antitumoral and pro-tumoral functions. 
on one hand, Vγ9Vδ2-T cells can control and suppress tumor development 
directly through potent cytotoxic capability and indirectly by regulating other 
innate and adaptive immune cells to establish antitumoral immune 
responses. First, Vγ9Vδ2-T cells can recognize and eliminate tumor cells with 
their potent killing ability. Second, they can promote dendritic cell maturation 
and macrophage activation. Third, Vγ9Vδ2-T cells can present antigens to 
αβ-T cells and iNKT cells. Fourth, they can stimulate and enhance NK cell 
antitumoral response. Finally, Vγ9Vδ2-T cells can help B cells produce 
antibodies. on the other hand, in the tumor microenvironment, the 
Vγ9Vδ2-T cells can be induced into Th-17-like cells and Treg-like cells by 
specific stimuli and they can secret immunosuppressive cytokines, such as 
IL-17, IL-10, and TGF-β, to suppress and modulate innate and adaptive 
antitumoral immunity. These strategies will be beneficial for tumor evasion/
growth, metastasis, and angiogenesis.
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through direct or indirect strategies (27). As mentioned above, 
the differentiation of unique subpopulations of Vγ9Vδ2-T cells 
with immunosuppressive features can be induced in the 
presence of specific stimuli, such as in the tumor-established 
microenvironment (Figure  2). For example, Vγ9Vδ2-T  cells 
may display Th2-, Th17-, or Treg-like profile and produce 
IL-4, IL-17, IL-10, and TGF-β, respectively. IL-10 and TGF-β 
are the cytokines with immunosuppressive activity, while IL-10 
can impair APC function of DCs, and induce the pro-tumoral 
functions of Vγ9Vδ2-T cells (131, 132). Some evidence indi-
cates that IL-17 produced by Th17-like Vγ9Vδ2-T  cells can 
directly promote the proliferation and dissemination of tumor 
cells in breast cancer (133). Most importantly, in the tumor 
microenvironment, IL-17 plays a critical regulatory role to 
other immune components, such as MDSCs and macrophage, 
and thus indirectly influences tumor immunosurveillance (42). 
Moreover, similar to classical Treg cells, the suppressive effect 
of regulatory-like Vγ9Vδ2-T cells also depends on cell-to-cell 
contact via CD86/CTLA-4 and PD-L1/PD-1 interactions 
between activated Vγ9Vδ2-T  cells and their responder cells 
(134) (Figure 3).
More recently, Peters et al. demonstrated that Vγ9Vδ2-T cell 
is a major source of IL-9 in vitro (135). According to this study, 
Vγ9Vδ2-T  cells can secret IL-9 when culturing with TGF-β 
and IL-15 and in the absence of IL-4. IL-9-producing CD8+ 
T cells and Th9 cells are always considered as new players in 
antitumoral immune responses (136–138); however, in some 
studies, IL-9 also displays potential pro-tumoral activity. Qiu 
et  al. found that in ALK+ anaplastic large-cell lymphoma, 
IL-9 can promote lymphoma cell proliferation and colony 
formation by regulating Jak3 activation in an autocrine man-
ner (139). Furthermore, IL-9 can abolish the establishment of 
immunological memory to tumor re-challenge and exhibits 
an immunomodulatory role in pro-tumoral immunity (140). 
Indeed, elevated serum IL-9 was found in the patients with 
metastatic breast cancer or diffuse large B-cell lymphoma 
(DLBCL) (141, 142). Meantime, Lv et al. found that IL-9 can 
support the survival of DLBCL cells and enhance the resistance 
of these tumor cells to chemotherapeutic drugs by upregulat-
ing p21CIP1 genes (141). Thus, in tumor immunity, the exact 
immunological roles of IL-9-producing Vγ9Vδ2-T  cells are 
still unknown. So far, the evidence for pro-tumoral activity of 
Vγ9Vδ2-T cells mostly comes from ex vivo experiments. More 
clinical evidence is needed to evaluate the potential pro-tumor 
ability of Vγ9Vδ2-T cells in vivo.
THeRAPeUTiC eFFeCTS OF  
vγ9vδ2-T CeLLS iN CLiNiCAL TRiALS
To date, two main therapeutic strategies based on Vγ9Vδ2-T cells 
have been proposed for tumor immunotherapy: the in  vivo 
expansion of Vγ9Vδ2-T  cells by aminobisphosphonates, and 
the adoptive transfer of ex vivo-expanded Vγ9Vδ2-T cells (143). 
Several clinical trials have been initiated to evaluate the safety 
and therapeutic efficacy of Vγ9Vδ2-T cell immunotherapy based 
on in vivo and ex vivo expansion. The clinical outcomes of these 
strategies have been confirmed in patients with different types 
of tumors, including leukemia/lymphoma, melanoma, RCC, 
hormone-refractory prostate cancer, breast cancer, NSCLC, CRC, 
MM, gastrointestinal tumors, ovarian cancer, cervical cancer, and 
bone cancer (45, 57). For instance, Wilhelm et al. first reported 
that administration of pamidronate and low-dose of IL-2 to 
expand Vγ9Vδ2-T  cells in  vivo was well tolerated and could 
induce objective tumor response in patients with low-grade non-
Hodgkin lymphoma or MM (18). Lang and coworkers conducted 
a pilot trial to determine the therapeutic effects of zoledronate 
with low-dose of IL-2 in patients with RCC (144). Furthermore, 
zoledronate with low dose of IL-2 have also been tested in treating 
prostate cancer and advanced breast cancer where partial remis-
sions haves been reported (14, 17). Bennouna et al. conducted a 
phase I study that, after treatment of bromohydrin pyrophosphate 
(BrHPP) and IL-2, in total of 28 patients, 12 patients had sta-
ble disease and 16 had progressive disease after three cycles of 
administration (145).
Adoptive transfer of zoledronate-expanded Vγ9Vδ2-T cells 
was reported to induce a complete remission of RCC patient with 
lung metastasis. (146). Kobayashi et al. also reported that adoptive 
transfer of Vγ9Vδ2-T cells in combination with zoledronate and 
IL-2 was well tolerated and the objective clinical responses could 
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be achieved in some patients with advanced RCC (147). More 
detailed information about clinical studies of Vγ9Vδ2-T  cells 
had been systematically reviewed in recent articles summarized 
by Deniger et al. and Kobayashi and Tanaka (45, 148).
Although these two strategies have yielded clinical success, 
there are still some limitations. For the in vivo expansion and 
activation of Vγ9Vδ2-T cells, one of the limitations is that the 
sustained proliferative activity is impaired, probably due to an 
energy or exhaustion of Vγ9Vδ2-T  cells induced by the suc-
cessive infusions of BrHPP and IL-2 (45, 149). Additionally, 
Kalyan et al. demonstrated that neutrophils in human periph-
eral blood could uptake of zoledronate and cause the sup-
pression of Vγ9Vδ2-T cells (150). Fowler et al. suggested that 
systemic use of zoledronate reduced the tumor homing ability 
of Vγ9Vδ2-T  cells (151). Indeed, repeated administration of 
zoledronate and IL-2 in the patients with breast cancer and RCC 
could inhibit the proliferative capacity of Vγ9Vδ2-T cells and 
reduced the responsiveness of Vγ9Vδ2-T cells to re-stimulation 
(144, 152). For the adoptive cell transfer therapy, the main 
problem is difficulty to expand Vγ9Vδ2-T  cells ex vivo from 
the advanced cancer patients with limited initial number of 
Vγ9Vδ2-T  cells, especially after radiotherapy and chemo-
therapy (45). Moreover, the effect of immunosuppressive tumor 
microenvironment on adoptively transferred Vγ9Vδ2-T cells is 
still not clear.
Up to now, aminobisphosphonates have only been found 
to target and stimulate Vγ9Vδ2-T cell subsets, but they do not 
target other subpopulations of γδ-T  cells, such as Vδ1-T  cells. 
Some synthetic phosphoantigens, such as BrHPP, HMBPP, and 
2-methyl-3-butenyl-1-pyrophosphate (2M3B1PP), are also 
found to activate and expand Vγ9Vδ2-T cells by mimicking the 
effects of aminobisphosphonates (153). Upon stimulation by 
these compounds, Vγ9Vδ2-T cells can enhance their antitumoral 
activities by release of IFN-γ and TNF-α (57). The administration 
of BrHPP was also tested in a Phase I study; the data showed 
that the BrHPP treatment was well tolerated and expansion of 
Vγ9Vδ2-T cells was successfully induced in patients with solid 
tumors (145). In addition to synthetic phosphoantigens, some 
monoclonal antibodies targeting γδ-TCR are also good candi-
dates for tumor immunotherapy. Starick et al. demonstrated that 
BTN3A (CD277)-specific monoclonal antibody 20.1 induced 
TCR-mediated activation of Vγ9Vδ2-T cells (154). This study not 
only provided the novel mechanisms involved in Vγ9Vδ2-T cell 
activation but also showed the potential for using BTN3A-specific 
antibodies to manipulate Vγ9Vδ2-T  cell immunity in tumor 
immunotherapy (154, 155).
Some recent studies have focused on the development of novel 
protocols to expand Vγ9Vδ2-T cells using immobilized antigens 
(156), agonistic monoclonal antibodies (15, 101), and tumor-
driven artificial antigen-presenting cells (157, 158). Meanwhile, 
Vγ9Vδ2-T cells are also amenable to genetic modifications via 
the introduction of αβ TCRs (159), and chimeric antigen recep-
tors (160). Furthermore, Vγ9Vδ2-T cells are suggested to act as a 
novel cellular vaccine to treat cancer patients (161).
CONCLUSiON
Recent advances in Vγ9Vδ2-T  cell research have paved a way 
for developing innovative therapeutic strategies for tumor 
immunotherapy. As discussed in this review, Vγ9Vδ2-T  cells 
can recognize tumor cells through TCR and other cell surface 
receptors, and their antitumoral activity is strictly regulated by 
activating and inhibitory receptors and their ligands. In addi-
tion, stimuli/cytokine milieu in tumor microenvironment can 
also induce pro-tumoral activity and functional plasticity of 
Vγ9Vδ2-T cells. Further study on the dual face of Vγ9Vδ2-T cells 
in tumor immunology could optimize current therapeutic proto-
cols and improve the therapeutic efficacy and clinical outcomes 
of Vγ9Vδ2-T cell-based tumor immunotherapy.
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